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Abstract
Background and Aims: The methylene-tetrahydrofolate dehydrogenase (NADP+ dependent) 1-like (MTHFD1L) gene is
involved in mitochondrial tetrahydrofolate metabolism. Polymorphisms in MTHFD1L, including rs6922269, have been
implicated in risk for coronary artery disease (CAD). We investigated the association between rs6922269 and known
metabolic risk factors and survival in two independent cohorts of coronary heart disease patients.
Methods and Results: DNA and plasma from 1940 patients with acute coronary syndromes were collected a median of 32
days after index hospital admission (Coronary Disease Cohort Study, CDCS). Samples from a validation cohort of 842
patients post-myocardial infarction (PMI) were taken 24–96 hours after hospitalization. DNA samples were genotyped for
rs6922269, using a TaqMan assay. Homocysteine and active vitamin B12 were measured by immunoassay in baseline CDCS
plasma samples, but not PMI plasma. All cause mortality was documented over follow-up of 4.1 (CDCS) and 8.8 (PMI) years,
respectively. rs6922269 genotype frequencies were AA n= 135, 7.0%; GA n= 785, 40.5% and GG n= 1020, 52.5% in the CDCS
and similar in the PMI cohort. CDCS patients with AA genotype for rs6922269 had lower levels of co-variate adjusted
baseline plasma active vitamin B12 (p = 0.017) and poorer survival than patients with GG or GA genotype (mortality: AA
19.6%, GA 12.0%, GG 11.6%; p = 0.007). In multivariate analysis, rs6922269 genotype predicted survival, independent of
established covariate predictors (p = 0.03). However the association between genotype and survival was not validated in the
PMI cohort.
Conclusion: MTHFD1L rs6922269 genotype is associated with active vitamin B12 levels at baseline and may be a marker of
prognostic risk in patients with established coronary heart disease.
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Introduction
Acute coronary syndromes (ACS) are conditions that result from
an acute reduction in perfusion of part of the coronary circulation,
including unstable angina and non-ST- and ST-elevation myo-
cardial infarction (MI). Genetic markers offer the promise of
identifying individual patients at increased risks of early disease-
onset, or worse prognosis, and who may benefit from additional
screening and early intervention. Genetic polymorphisms have
been associated with increased risk for ACS [1,2,3], but the
number of reports investigating genetic association with clinical
outcome following specific ACS events is comparatively few
[4,5,6].
A genetic locus implicated in two independent genome-wide
association studies (GWAS) of coronary artery disease (CAD) [7,8]
is the methylene-tetrahydrofolate dehydrogenase (NADP+ depen-
dent) 1-like (MTHFD1L) gene. Single nucleotide polymorphisms
(SNPs) from ,20 kb of MTHFD1L, represented by the lead
polymorphism, rs6922269, have been significantly associated with
the development of CAD in several GWAS [7,8]. The adjusted
population attributable risk fraction for myocardial infarction (MI)
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from the German MI Family Study was reported as 11%
(p= 0.009) for the rs6922269 A allele [8], and a recent meta-
analysis confirmed its association with CHD risk [9].
Although rs6922269 has been associated with risk of developing
CAD in several GWAS, genetic association studies of rs6922269
with clinical outcome in patients with established CAD are limited
[10,11]. We hypothesized that rs6922269 would be associated with
mortality after hospital admission for ACS, and investigated its
association with baseline characteristics, natriuretic peptides, other
clinical risk factors and survival in a cohort of 1940 patients
recruited after hospital admission for ACS and followed for over 4
years. We then sought validation of our findings in an independent
cohort of 842 post-MI patients followed for 8.8 years. To
investigate association with relevant metabolic risk factors we
hypothesized that homocysteine and active vitamin B12 plasma
levels would be perturbed in patients with the high-risk genotype
of rs6922269, reflecting the role of MTHFD1L in folate
metabolism. Availability of suitable plasma samples limited these
folate pathway metabolite assays to a subset of the CDCS cohort.
Methods
Study population
Coronary Disease Cohort Study. The Coronary Disease
Cohort Study (CDCS) recruited 1940 patients after admission to
Christchurch or Auckland City Hospitals with a diagnosis of ACS,
between July 2002 and January 2009. Inclusion criteria have been
described previously [12]. Patients were excluded from the study if
they had a severe co-morbidity that limited their life expectancy to
,3 years (eg. end-stage renal failure, cancer). The aim of the study
was to include a broad spectrum of age, both genders and
significant sub-groups with established risk factors for CHD
including those with hypertension and diabetes. Plasma was
collected at a baseline clinic, at a median 32 days after the index
admission for ACS. We collected demographic and clinical data at
baseline including blood pressure, height, weight, ECG, echocar-
diography, family and personal medical history and medication.
Plasma samples were assayed for BNP and NT-proBNP. Patients
were followed for a median of 4.06 (range 0.12–7.92) years.
Patients attended follow-up clinics 3–5 months and 12–14 months
post-onset of ACS and participants completed questionnaires at
two years and three years post-discharge. Standardized transtho-
racic echocardiography was performed using a GE Vivid 3
ultrasound system (GE Medical Systems, Auckland) at Christch-
urch Hospital and an ATL HDI 5000 (Philips Healthcare, Sydney)
at Auckland City Hospital as described previously [5]. The New
Zealand Multi-Region Ethics Committee approved the study. All
participating patients provided written, informed consent.
Post-Myocardial Infarction Study. Patients (n = 842) were
recruited into the Post-Myocardial Infarction (PMI) study between
November 1994 and June 2001. The study assessed the prognostic
utility of a range of circulating biomarkers after MI and has been
described in detail elsewhere [13]. Acute MI (including ST
elevation, STEMI, and non-ST elevation infarction, NSTEMI)
was defined by the presence of typical cardiac ischemic symptoms,
ischemic change in two or more contiguous EKG leads, and peak
elevation of plasma creatine kinase .400 U/L. Patients were
excluded if they were .80 years, had cardiogenic shock or did not
survive the first 24 hours after admission. Although not an
inclusion criterion, all patients were troponin T positive (0.1 mg/
Figure 1. A boxplot comparison of log-transformed plasma active vitamin B12 levels at baseline post-admssion in rs6922269
genotype groups. The p-value compares data adjusted for age and hypertensive status. 1Geometric means.
doi:10.1371/journal.pone.0089029.g001
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L). Median follow-up was 8.8 (0.1–13.0) years. The Canterbury
Ethics Committee approved the study, and participating patients
provided written informed consent.
Clinical events
Clinical events were determined from recruitment question-
naires, planned follow-up clinic visits, consultation of patient notes,
the National Health Information Service and hospital Patient
Management System databases. Survival times were calculated
from the date of index admission. The investigation conforms to
the principles outlined in the Declaration of Helsinki and Title 45,
U.S. Code of Federal Regulations, Part 46.
Neurohormone and analyte measurements
Plasma samples were collected and stored in sealed tubes at 2
80uC. Circulating levels of natriuretic peptides were assayed as
previously described [13]. NTproBNP plasma levels were stable
for at least 18 months under these conditions. Plasma samples
from each subject were analysed soon after the patient’s 12-month
clinic, so storage times from collection to analysis were similar in
the two studies. Three sets of QC samples were measured in each
assay and were overlapped with new QC samples for subsequent
batches. No long-term drift was noted in the assay with QC
samples. Sample storage is therefore unlikely to have influenced
our results. Levels of creatine kinase (CK) and troponin T were
measured using ELISA kits (Roche Diagnostics, Auckland).
Homocysteine and active vitamin B12 were assayed by immuno-
assay on an automated Abbott ARCHITECT ci8200 Analyzer
(Abbott Laboratories) by standard kit procedures in a laboratory
accredited by International Accreditation New Zealand.
DNA Extraction and rs6922269 polymorphism
genotyping
Extraction of genomic DNA for genotyping was performed as
described previously [5]. DNA samples were genotyped for the
rs6922269 polymorphism in 10 mL reaction volumes using allele-
specific TaqMan genotyping probes (Applied Biosystems, USA),
including 16 Thermo qPCR ROX Mix (Thermo, UK) and
100 ng of genomic DNA in a Roche LC480 (Roche Diagnostics,
Auckland).
Statistical analysis
Univariate analyses to test for associations between rs6922269
genotype and demographic, neurohormonal and echocardio-
graphic measurements were performed using x2 and ANOVA
tests. Skewed data were log-transformed before analysis and
geometric means with 95% confidence intervals reported. The
survival of genotype groups was compared using Kaplan-Meier
analysis and the log-rank test. Independent associations between
genotype and survival were tested using Cox proportional hazards
multivariate analysis including the following established predictors;
age [14,15], gender [16], previous MI [15], antecedent hyperten-
sion [17], drug treatment [18], physical activity [19], and NT-
proBNP levels [13]. We dichotomized plasma NT-proBNP levels
above and below median values as previously described [20], to
investigate any interaction between rs6922269 genotype and NT-
proBNP levels. Ethnicity was self-declared and categorized as
Maori/Pacific Islander, European, Other or Unknown. The study
had power to detect a HR of .1.81 as statistically significant (two
tailed p,0.05, 80% power) in the CDCS cohort. An additive
genetic model was used unless stated otherwise. All analyses were
performed using SPSS version 19 (SPSS Inc. Chicago, IL).
Statistical significance was set at the 5% level (p,0.05).
Figure 2. Kaplan-Meier survival analysis of CDCS cohort patients stratified by rs6922269 genotype.
doi:10.1371/journal.pone.0089029.g002
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Results
rs6922269 Genotype and CDCS cohort data
Genotypes were obtained for 1940 patients from the CDCS
cohort for the MTHFD1L rs6922269 SNP. Baseline patient
characteristics for each genotype group are shown in Table S1
in File S1. Genotype frequencies were AA, 7.0%; GA, 40.5% and
GG, 52.5% (minor allele frequency = 0.272) and conformed to the
Hardy-Weinberg equilibrium (p= 0.9998). Minor allele frequency
(MAF) did not differ between ethnic groups in either cohort (p.
0.134). Patients with AA genotype had markedly higher plasma
creatinine at baseline (p = 0.008) and trended towards having
lower LVEF (p= 0.086). Active vitamin B12 levels assayed from
plasma samples taken at the patients’ baseline clinic were lower in
patients with AA genotype when adjusted for age and hypertensive
status (Figure 1). Correction for multiple testing transformed these
p-values to .0.05. No significant association with homocysteine
levels at baseline was detected.
Figure 3. Kaplan-Meier analysis of event free survival to a) first HF admission, b) first NSTEMI admission stratified by rs6922269
genotype.
doi:10.1371/journal.pone.0089029.g003
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rs6922269 Genotype and clinical outcome in the CDCS
cohort
Survival in the patients with GG and GA genotypes was similar
over the course of the follow-up period of a median of 4.06 (0.12–
7.92) years, and was significantly greater than the AA patient
group (mortality: AA 23.1%, GA 16.6%, GG 15.6%; p= 0.043)
(Figure 2). An allelic test for association with survival was also
significant (p = 0.035). rs6922269 genotype was significantly
associated with first admission for NSTEMI (AA 28.1%, GA
21.5%, GG 22.4%; p= 0.029) and trended towards association
with first admission for heart failure (AA 22.3%, GA 17.2%, GG
15.7%; p= 0.063) (Figure 3), but not admission for acute MI,
STEMI, unstable angina or stroke (p.0.122).
In multivariate analysis, rs6922269 genotype was an indepen-
dent predictor of mortality in a Cox proportional hazards model
including age, gender, ethnicity, antecedent hypertension, prior
MI, physical activity score, statin and b-blocker treatment and
plasma BNP levels (Table S2 in File S1). Genotype was a
significant predictor of mortality (poverall = 0.049; AA versus GG
HR=1.63, p= 0.025; GA versus GG HR=1.22, p = 0.125; AA
versus GA/GG HR=1.23, p = 0.053). The Kaplan-Meier plots
shown in Figure 4 illustrate that the majority of mortality occurred
in the group of patients with above median NT-proBNP levels at
baseline and genotype was significantly associated with mortality
in this subgroup. This interaction was also significant (p = 0.001).
rs6922269 Genotype and the PMI cohort
In order to validate the results from the CDCS cohort, 842
patients from the PMI cohort were genotyped for rs6922269.
Genotype frequencies were AA 6.7%, GA 39.4% and GG 53.9%
(MAF=0.264). Patient characteristics for the PMI cohort stratified
by genotype are shown in Table S3 in File S1. The prevalence of
prior MI was greater in patients with an AA genotype (p= 0.025)
and treatment at discharge with lipid lowering drugs trended
towards being more common in this group also (p = 0.067).
Survival over a median 8.8 (0.1–13.0) years follow-up was not
significantly associated with rs6922269 genotype or alleles in the
PMI cohort, either in a univariate (Figure 5) or multivariate
analysis (Table S4 in File S1). Survival was not associated with
genotype in either strata after dichotomization of the cohort by
median NT-proBNP level (p.0.45), or presence or absence of a
diagnosis of ST-elevation MI (p.0.56). However, if follow-up was
truncated at 6 years and A-allele carriers grouped there was a
trend towards an association between genotype and survival
(n = 842, mortality: GG, 14.6% GA/AA 18.8%, p= 0.094).
Suitable plasma samples were not available at the time of data
generation, to allow assay for homocysteine and/or active vitamin
B12 in the PMI study.
Discussion
Mortality in patients with the AA genotype for rs6922269 was
significantly greater than patients with GA or GG genotype in the
CDCS cohort, limited to those patients with above median NT-
proBNP levels at baseline, suggesting rs6922269 genotype may be
useful in further risk stratification of these patients, already with a
poor prognosis. Possibly only those with high NT-proBNP express
the additional genetic risk of AA genotype, potentially mediated
through vitamin B12 levels. Patients with an AA genotype had
higher plasma creatinine levels and lower active vitamin B12 levels
at baseline, indicating poorer kidney function and higher CVD
risk. Inclusion of rs6922269 genotype in a Cox proportional
hazards model including established predictors of mortality from
similar cohorts, demonstrated genotype was an independent
predictor of mortality.
The prognostic value of the rs6922269 genotype for mortality
was not strongly replicated in the PMI cohort. While a hint of an
allele-A dominant association with PMI cohort mortality prior to 6
years of follow-up was detected, this was much weaker than the
association with mortality observed in the CDCS cohort.
Figure 4. Kaplan-Meier survival analysis of CDCS cohort stratified by rs6922269 genotype a) in patients with above median BNP
levels, b) in patients with below median BNP levels.
doi:10.1371/journal.pone.0089029.g004
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Differences between the cohorts may have obscured a genetic
association, such as the much longer follow-up period, smaller size
of the PMI cohort and a much more frequent diagnosis of STEMI
in PMI patients (CDCS 9.6%; PMI 82.2%). However, subgroup
analysis did not reveal an association with genotype in the PMI
NSTEMI subgroup.
While the functional effect of rs6922269 is currently unknown, a
possible mechanism through which MTHFD1L polymorphisms
may affect CHD risk, and potentially clinical outcomes, is by
influencing folate pathway metabolite levels. When adjusted for
age and hypertensive status a significant association between active
vitamin B12 levels and rs6922269 genotype is revealed. While
Figure 5. Kaplan-Meier survival analysis of PMI cohort patients stratified by rs6922269 genotype.
doi:10.1371/journal.pone.0089029.g005
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correction for these particular covariates is not entirely intuitive,
hypertension has been associated with reduced vitamin B12 levels
[21]. Defects in the C1-tetrahydrofolate metabolic pathway may
decrease the levels of vitamin B12. It is possible that the
inconsistent findings associating rs6922269 with various heart
disease phenotypes in this and other studies [7,8,10,22] may be
due in part to MTHFD1L gene-environment interactions, partic-
ularly dietary variation in folate content leading to variation in
folate metabolite levels and therefore risks of disease progression.
Folate status and drug treatment regimen have undergone
substantial changes in New Zealand during the decade between
the median dates of recruitment for each cohort [23,24]. However
it must be acknowledge that this interpretation of the data is
circumstantial and as such should be viewed as hypothesis
generating. Further studies of the utility of rs6922269 as a
diagnostic and prognostic marker in CHD patients are needed,
with particular emphasis on participants’ dietary intake and
nutritional status, especially folate pathway metabolites.
While a recent large meta-analysis of GWAS markers for
dyslipidaemia, diabetes and CHD found rs6922269 was associated
with CHD risk [9], investigation of the association of rs6922269
with survival in patients with established CAD has been limited. A
recent GWAS of mortality after ACS identified rs6922269 as the
only SNP of 95 investigated to achieve Bonferroni-corrected
significant association with mortality in the test cohort (n = 811,
p = 0.007). This finding was replicated in the African-American
subgroup of a second cohort (p = 0.015), but not in two additional
independent cohorts [11], resonant with our own results.
In conclusion MTHFD1L rs6922269 genotype proved to be an
inconsistent marker of prognostic risk in two cohorts of patients
with coronary heart disease, possibly because of gene-environment
effects.
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